- Eurepa V 1/0.2 mg Tablet helps in controlling blood sugar levels in Type 2 diabetes patients.
- This medication is effective in reducing postprandial hyperglycemia.
- Eurepa V 1/0.2 mg Tablet can be used alongside diet and exercise for optimal results.
- The combination of Repaglinide and Voglibose in Eurepa V 1/0.2 mg Tablet enhances glycemic control.
- Patients can experience fewer blood sugar spikes after meals with Eurepa V 1/0.2 mg Tablet.
- Eurepa V 1/0.2 mg Tablet is beneficial for those who have difficulty managing diabetes with lifestyle changes alone.
- This formulation aids in preventing complications associated with uncontrolled diabetes.
- Eurepa V 1/0.2 mg Tablet supports overall metabolic health by regulating glucose levels.
- Regular use of Eurepa V 1/0.2 mg Tablet can lead to improved quality of life for diabetic patients.
- The medication is designed for easy administration, making it convenient for daily use.
- Eurepa V 1/0.2 mg Tablet can be an integral part of a comprehensive diabetes management plan.
- Patients using Eurepa V 1/0.2 mg Tablet may find it easier to maintain their target blood glucose levels.
Eurepa V 1/0.2 mg Tablet - Strip of 10
Prescription Required
Compositions : Repaglinide 1mg + Voglibose 0.2mg
₹175.12
(Incl. GST)
MRP :
(Incl. GST)
MRP :
In stock
Delivery within 2 to 7 Working Days
Manufacture/Marketer: Torrent Pharmaceuticals Ltd
Door Step Delivery
Quick and Secure
No Hidden Charges
Pay only what's shown
18K Pincodes Served
With Trust & Reliability
Description
Eurepa V 1/0.2 mg Tablet is a specialized pharmaceutical formulation designed for the management of Type 2 diabetes mellitus. This medication combines two active ingredients, Repaglinide and Voglibose, which work synergistically to help control blood sugar levels effectively. The primary purpose of Eurepa V 1/0.2 mg Tablet is to enhance glycemic control in patients who are unable to achieve adequate blood glucose levels through diet and exercise alone. As a combination therapy, Eurepa V 1/0.2 mg Tablet falls under the therapeutic category of antidiabetic agents, specifically targeting postprandial hyperglycemia. The unique composition of Eurepa V 1/0.2 mg Tablet allows for rapid action, making it an essential part of diabetes management for many patients. By utilizing the properties of Repaglinide, a rapid-acting insulin secretagogue, and Voglibose, an alpha-glucosidase inhibitor, Eurepa V 1/0.2 mg Tablet effectively reduces blood sugar spikes after meals. This dual-action approach not only aids in maintaining stable glucose levels but also minimizes the risk of complications associated with diabetes. Patients using Eurepa V 1/0.2 mg Tablet can expect improved overall glycemic control, which is crucial for long-term health outcomes. The formulation is particularly beneficial for those who struggle with managing their diabetes through lifestyle changes alone. With its carefully balanced composition, Eurepa V 1/0.2 mg Tablet represents a significant advancement in diabetes care, providing patients with a reliable option to manage their condition effectively.
Product Details
Uses & Benefits
How Eurepa V 1/0.2 mg Tablet works
Eurepa V 1/0.2 mg Tablet works through a combination of two mechanisms provided by its active ingredients, Repaglinide and Voglibose. These components work together to improve glycemic control in patients with Type 2 diabetes mellitus.
Eurepa V 1/0.2 mg Tablet works through a combination of two mechanisms provided by its active ingredients, Repaglinide and Voglibose. These components work together to improve glycemic control in patients with Type 2 diabetes mellitus.
- Repaglinide: Stimulates the pancreas to release insulin quickly after meals, helping to lower blood sugar levels effectively.
- Voglibose: Inhibits the enzyme alpha-glucosidase in the intestines, slowing down carbohydrate absorption and reducing post-meal glucose spikes.
- The combination allows for better overall management of blood glucose levels compared to using either medication alone.
- Eurepa V 1/0.2 mg Tablet helps maintain stable insulin levels throughout the day.
- This dual-action mechanism minimizes the risk of hypoglycemia when used appropriately.
- By addressing both insulin secretion and carbohydrate absorption, Eurepa V 1/0.2 mg Tablet provides comprehensive diabetes management.
How to use Eurepa V 1/0.2 mg Tablet
- Eurepa V 1/0.2 mg Tablet should be taken approximately 15 minutes before a main meal.
- The recommended dosage is typically one tablet per meal, but this may vary based on individual needs.
- Frequency of administration should align with meal patterns; do not exceed the prescribed amount.
- Consult a healthcare provider for personalized dosage adjustments based on blood sugar monitoring.
- Duration of treatment with Eurepa V 1/0.2 mg Tablet should be determined by a healthcare professional based on individual response and control of blood glucose levels.
- Special instructions include monitoring blood sugar regularly to avoid hypoglycemia.
- Always carry a source of fast-acting sugar to manage potential low blood sugar episodes while using Eurepa V 1/0.2 mg Tablet.
Lifestyle Advice
- Maintain a balanced diet rich in whole grains, vegetables, and lean proteins while using Eurepa V 1/0.2 mg Tablet.
- Engage in regular physical activity to enhance the effectiveness of Eurepa V 1/0.2 mg Tablet in controlling blood sugar levels.
- Avoid skipping meals to prevent fluctuations in blood glucose levels while on Eurepa V 1/0.2 mg Tablet.
- Stay hydrated and limit sugary beverages that can interfere with diabetes management when using Eurepa V 1/0.2 mg Tablet.
- Regularly check blood sugar levels as advised by your healthcare provider while taking Eurepa V 1/0.2 mg Tablet.
Safety Advice
Side Effects
Side Effects
- Common side effects of Eurepa V 1/0.2 mg Tablet include diarrhea and abdominal pain.
- Hypoglycemia (low blood sugar) is a potential side effect; symptoms may include cold sweats, tremors, and anxiety.
- Upper respiratory tract infections may occur in some patients using Eurepa V 1/0.2 mg Tablet.
- Headaches are also reported among users of this medication.
- If side effects persist or worsen, consult a healthcare provider immediately.
- Serious side effects may include severe hypoglycemia; seek medical attention if symptoms are severe or unmanageable.
Precautions and Warnings
Precautions & Warnings
- Eurepa V 1/0.2 mg Tablet should not be used by individuals with known hypersensitivity to Repaglinide or Voglibose.
- Patients with severe liver or kidney impairment should avoid using this medication without medical advice.
- Alcohol consumption may increase the risk of hypoglycemia when taking Eurepa V 1/0.2 mg Tablet; moderation is advised.
- Pregnant or breastfeeding women should consult their healthcare provider before using Eurepa V 1/0.2 mg Tablet.
- Driving or operating heavy machinery should be approached with caution until individual responses to the medication are known.
- Regular monitoring of blood glucose levels is essential while using Eurepa V 1/0.2 mg Tablet to prevent complications.
FAQs
1. What is Eurepa V 1/0.2 mg Tablet used for?
Eurepa V 1/0.2 mg Tablet is primarily used for managing Type 2 diabetes mellitus by controlling blood sugar levels.
2. How should I take Eurepa V 1/0.2 mg Tablet?
Eurepa V 1/0.2 mg Tablet should be taken approximately 15 minutes before meals for optimal effectiveness.
3. What are the common side effects of Eurepa V 1/0.2 mg Tablet?
Common side effects include diarrhea, abdominal pain, and hypoglycemia, which may present as cold sweats or tremors.
4. Can I drink alcohol while taking Eurepa V 1/0.2 mg Tablet?
Alcohol consumption should be limited as it can increase the risk of hypoglycemia when taking Eurepa V 1/0.2 mg Tablet.
5. Who should avoid using Eurepa V 1/0.2 mg Tablet?
Individuals with severe liver or kidney impairment or those allergic to its components should avoid using Eurepa V 1/0.2 mg Tablet.
6. How does Eurepa V 1/0.2 mg Tablet work?
Eurepa V 1/0.2 mg Tablet works by combining Repaglinide, which stimulates insulin release, and Voglibose, which slows carbohydrate absorption.
7. What should I do if I miss a dose of Eurepa V 1/0.2 mg Tablet?
If you miss a dose of Eurepa V 1/0.2 mg Tablet, take it as soon as you remember unless it's close to your next scheduled dose.
Eurepa V 1/0.2 mg Tablet is primarily used for managing Type 2 diabetes mellitus by controlling blood sugar levels.
2. How should I take Eurepa V 1/0.2 mg Tablet?
Eurepa V 1/0.2 mg Tablet should be taken approximately 15 minutes before meals for optimal effectiveness.
3. What are the common side effects of Eurepa V 1/0.2 mg Tablet?
Common side effects include diarrhea, abdominal pain, and hypoglycemia, which may present as cold sweats or tremors.
4. Can I drink alcohol while taking Eurepa V 1/0.2 mg Tablet?
Alcohol consumption should be limited as it can increase the risk of hypoglycemia when taking Eurepa V 1/0.2 mg Tablet.
5. Who should avoid using Eurepa V 1/0.2 mg Tablet?
Individuals with severe liver or kidney impairment or those allergic to its components should avoid using Eurepa V 1/0.2 mg Tablet.
6. How does Eurepa V 1/0.2 mg Tablet work?
Eurepa V 1/0.2 mg Tablet works by combining Repaglinide, which stimulates insulin release, and Voglibose, which slows carbohydrate absorption.
7. What should I do if I miss a dose of Eurepa V 1/0.2 mg Tablet?
If you miss a dose of Eurepa V 1/0.2 mg Tablet, take it as soon as you remember unless it's close to your next scheduled dose.
Instructions
Directions for Use
Use only as prescribed by your physician.
Storage and Disposal
- Store in a cool, dry place below 30°C.
- Protect from light and moisture.
- Keep out of reach of children.
- Dispose of unused tablets as per pharmacist's advice.
More Information
| SKU | 443023 |
|---|---|
| Country of Manufacture | India |
| Manufacturer Address | Torrent Pharmaceuticals Ltd |
| Return/Buy Back policy | Non-returnable |
| Prescription Required | Yes |
| Storage |
|
| Seller | Kogland Commerce Pvt Ltd (TN) |
Eurepa V 1/0.2 mg Tablet is a specialized pharmaceutical formulation designed for the management of Type 2 diabetes mellitus. This medication combines two active ingredients, Repaglinide and Voglibose, which work synergistically to help control blood sugar levels effectively. The primary purpose of Eurepa V 1/0.2 mg Tablet is to enhance glycemic control in patients who are unable to achieve adequate blood glucose levels through diet and exercise alone. As a combination therapy, Eurepa V 1/0.2 mg Tablet falls under the therapeutic category of antidiabetic agents, specifically targeting postprandial hyperglycemia. The unique composition of Eurepa V 1/0.2 mg Tablet allows for rapid action, making it an essential part of diabetes management for many patients. By utilizing the properties of Repaglinide, a rapid-acting insulin secretagogue, and Voglibose, an alpha-glucosidase inhibitor, Eurepa V 1/0.2 mg Tablet effectively reduces blood sugar spikes after meals. This dual-action approach not only aids in maintaining stable glucose levels but also minimizes the risk of complications associated with diabetes. Patients using Eurepa V 1/0.2 mg Tablet can expect improved overall glycemic control, which is crucial for long-term health outcomes. The formulation is particularly beneficial for those who struggle with managing their diabetes through lifestyle changes alone. With its carefully balanced composition, Eurepa V 1/0.2 mg Tablet represents a significant advancement in diabetes care, providing patients with a reliable option to manage their condition effectively.
Uses & Benefits
- Eurepa V 1/0.2 mg Tablet helps in controlling blood sugar levels in Type 2 diabetes patients.
- This medication is effective in reducing postprandial hyperglycemia.
- Eurepa V 1/0.2 mg Tablet can be used alongside diet and exercise for optimal results.
- The combination of Repaglinide and Voglibose in Eurepa V 1/0.2 mg Tablet enhances glycemic control.
- Patients can experience fewer blood sugar spikes after meals with Eurepa V 1/0.2 mg Tablet.
- Eurepa V 1/0.2 mg Tablet is beneficial for those who have difficulty managing diabetes with lifestyle changes alone.
- This formulation aids in preventing complications associated with uncontrolled diabetes.
- Eurepa V 1/0.2 mg Tablet supports overall metabolic health by regulating glucose levels.
- Regular use of Eurepa V 1/0.2 mg Tablet can lead to improved quality of life for diabetic patients.
- The medication is designed for easy administration, making it convenient for daily use.
- Eurepa V 1/0.2 mg Tablet can be an integral part of a comprehensive diabetes management plan.
- Patients using Eurepa V 1/0.2 mg Tablet may find it easier to maintain their target blood glucose levels.
How Eurepa V 1/0.2 mg Tablet works
Eurepa V 1/0.2 mg Tablet works through a combination of two mechanisms provided by its active ingredients, Repaglinide and Voglibose. These components work together to improve glycemic control in patients with Type 2 diabetes mellitus.
Eurepa V 1/0.2 mg Tablet works through a combination of two mechanisms provided by its active ingredients, Repaglinide and Voglibose. These components work together to improve glycemic control in patients with Type 2 diabetes mellitus.
- Repaglinide: Stimulates the pancreas to release insulin quickly after meals, helping to lower blood sugar levels effectively.
- Voglibose: Inhibits the enzyme alpha-glucosidase in the intestines, slowing down carbohydrate absorption and reducing post-meal glucose spikes.
- The combination allows for better overall management of blood glucose levels compared to using either medication alone.
- Eurepa V 1/0.2 mg Tablet helps maintain stable insulin levels throughout the day.
- This dual-action mechanism minimizes the risk of hypoglycemia when used appropriately.
- By addressing both insulin secretion and carbohydrate absorption, Eurepa V 1/0.2 mg Tablet provides comprehensive diabetes management.
How to use Eurepa V 1/0.2 mg Tablet
- Eurepa V 1/0.2 mg Tablet should be taken approximately 15 minutes before a main meal.
- The recommended dosage is typically one tablet per meal, but this may vary based on individual needs.
- Frequency of administration should align with meal patterns; do not exceed the prescribed amount.
- Consult a healthcare provider for personalized dosage adjustments based on blood sugar monitoring.
- Duration of treatment with Eurepa V 1/0.2 mg Tablet should be determined by a healthcare professional based on individual response and control of blood glucose levels.
- Special instructions include monitoring blood sugar regularly to avoid hypoglycemia.
- Always carry a source of fast-acting sugar to manage potential low blood sugar episodes while using Eurepa V 1/0.2 mg Tablet.
Lifestyle Advice
- Maintain a balanced diet rich in whole grains, vegetables, and lean proteins while using Eurepa V 1/0.2 mg Tablet.
- Engage in regular physical activity to enhance the effectiveness of Eurepa V 1/0.2 mg Tablet in controlling blood sugar levels.
- Avoid skipping meals to prevent fluctuations in blood glucose levels while on Eurepa V 1/0.2 mg Tablet.
- Stay hydrated and limit sugary beverages that can interfere with diabetes management when using Eurepa V 1/0.2 mg Tablet.
- Regularly check blood sugar levels as advised by your healthcare provider while taking Eurepa V 1/0.2 mg Tablet.
Side Effects
Side Effects
- Common side effects of Eurepa V 1/0.2 mg Tablet include diarrhea and abdominal pain.
- Hypoglycemia (low blood sugar) is a potential side effect; symptoms may include cold sweats, tremors, and anxiety.
- Upper respiratory tract infections may occur in some patients using Eurepa V 1/0.2 mg Tablet.
- Headaches are also reported among users of this medication.
- If side effects persist or worsen, consult a healthcare provider immediately.
- Serious side effects may include severe hypoglycemia; seek medical attention if symptoms are severe or unmanageable.
Precautions and Warnings
Precautions & Warnings
- Eurepa V 1/0.2 mg Tablet should not be used by individuals with known hypersensitivity to Repaglinide or Voglibose.
- Patients with severe liver or kidney impairment should avoid using this medication without medical advice.
- Alcohol consumption may increase the risk of hypoglycemia when taking Eurepa V 1/0.2 mg Tablet; moderation is advised.
- Pregnant or breastfeeding women should consult their healthcare provider before using Eurepa V 1/0.2 mg Tablet.
- Driving or operating heavy machinery should be approached with caution until individual responses to the medication are known.
- Regular monitoring of blood glucose levels is essential while using Eurepa V 1/0.2 mg Tablet to prevent complications.
1. What is Eurepa V 1/0.2 mg Tablet used for?
Eurepa V 1/0.2 mg Tablet is primarily used for managing Type 2 diabetes mellitus by controlling blood sugar levels.
2. How should I take Eurepa V 1/0.2 mg Tablet?
Eurepa V 1/0.2 mg Tablet should be taken approximately 15 minutes before meals for optimal effectiveness.
3. What are the common side effects of Eurepa V 1/0.2 mg Tablet?
Common side effects include diarrhea, abdominal pain, and hypoglycemia, which may present as cold sweats or tremors.
4. Can I drink alcohol while taking Eurepa V 1/0.2 mg Tablet?
Alcohol consumption should be limited as it can increase the risk of hypoglycemia when taking Eurepa V 1/0.2 mg Tablet.
5. Who should avoid using Eurepa V 1/0.2 mg Tablet?
Individuals with severe liver or kidney impairment or those allergic to its components should avoid using Eurepa V 1/0.2 mg Tablet.
6. How does Eurepa V 1/0.2 mg Tablet work?
Eurepa V 1/0.2 mg Tablet works by combining Repaglinide, which stimulates insulin release, and Voglibose, which slows carbohydrate absorption.
7. What should I do if I miss a dose of Eurepa V 1/0.2 mg Tablet?
If you miss a dose of Eurepa V 1/0.2 mg Tablet, take it as soon as you remember unless it's close to your next scheduled dose.
Eurepa V 1/0.2 mg Tablet is primarily used for managing Type 2 diabetes mellitus by controlling blood sugar levels.
2. How should I take Eurepa V 1/0.2 mg Tablet?
Eurepa V 1/0.2 mg Tablet should be taken approximately 15 minutes before meals for optimal effectiveness.
3. What are the common side effects of Eurepa V 1/0.2 mg Tablet?
Common side effects include diarrhea, abdominal pain, and hypoglycemia, which may present as cold sweats or tremors.
4. Can I drink alcohol while taking Eurepa V 1/0.2 mg Tablet?
Alcohol consumption should be limited as it can increase the risk of hypoglycemia when taking Eurepa V 1/0.2 mg Tablet.
5. Who should avoid using Eurepa V 1/0.2 mg Tablet?
Individuals with severe liver or kidney impairment or those allergic to its components should avoid using Eurepa V 1/0.2 mg Tablet.
6. How does Eurepa V 1/0.2 mg Tablet work?
Eurepa V 1/0.2 mg Tablet works by combining Repaglinide, which stimulates insulin release, and Voglibose, which slows carbohydrate absorption.
7. What should I do if I miss a dose of Eurepa V 1/0.2 mg Tablet?
If you miss a dose of Eurepa V 1/0.2 mg Tablet, take it as soon as you remember unless it's close to your next scheduled dose.
Directions for Use
Use only as prescribed by your physician.
Storage and Disposal
- Store in a cool, dry place below 30°C.
- Protect from light and moisture.
- Keep out of reach of children.
- Dispose of unused tablets as per pharmacist's advice.
| SKU | 443023 |
|---|---|
| Country of Manufacture | India |
| Manufacturer Address | Torrent Pharmaceuticals Ltd |
| Return/Buy Back policy | Non-returnable |
| Prescription Required | Yes |
| Storage |
|
| Seller | Kogland Commerce Pvt Ltd (TN) |
Door Step Delivery
Quick and Secure
No Hidden Charges
Pay only what's shown
18K Pincodes Served
With Trust & Reliability
Customer Reviews
No reviews yet
Be the first to share your thoughts. Honest feedback helps other shoppers and us serve you better.
Write Your Own Review
Only registered users can write reviews. Please Sign in or create an account